Physician profile
Davy Krang
NPI 1770326142
$470.54
in general payments reported to CMS, 2019-2025
12 companies · $322 in 2025
The $322 reported for 2025 was more than what 86% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $148 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $136.64 | 2024-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $96.56 | 2024-2025 | |
| Glaxosmithkline, LLC. | $56.19 | 2025 | Bexsero, Penmenvy |
| Collegium Pharmaceutical, INC. | $30.23 | 2025 | Jornay Pm |
| Ars Pharmaceuticals Operations, INC. | $28.58 | 2025 | Neffy |
| Seqirus USA INC | $21.98 | 2025 | Flucelvax |
| Verrica Pharmaceuticals INC. | $20.29 | 2024 | Ycanth |
| Phadia US INC. | $19.62 | 2025 | Immunocap |
| Merck Sharp & Dohme LLC | $17.13 | 2024 | Vaxneuvance, Gardasil, Vaqta |
| Pfizer INC. | $15.80 | 2024 | |
| Ironshore Pharmaceuticals INC. | $15.55 | 2024 | |
| Organon LLC | $11.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davy Krang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.